INmune Bio submits EMA orphan drug application for Ebstrocel in RDEB

PUBT · 1d ago
INmune Bio submits EMA orphan drug application for Ebstrocel in RDEB
  • INmune Bio filed with the EMA for orphan drug designation for Ebstrocel in recessive dystrophic epidermolysis bullosa.
  • A separate EMA scientific advice package was submitted to support a planned EU marketing authorization application in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260700PRIMZONEFULLFEED9816003) on August 26, 2026, and is solely responsible for the information contained therein.